Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for improving glycemic control in type 2 diabetes patients with inadequate glycemic control despite metformin therapy.
1. A method for treating type 2 diabetes mellitus in a patient with inadequate glycemic control despite therapy with metformin, said method comprising orally administering 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine to said patient in an amount of 5 mg per day in combination with metformin.
2. A method for treating type 2 diabetes mellitus in a patient with inadequate glycemic control despite therapy with metformin, said method comprising orally administering 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine to said patient in an amount of 5 mg per day as add-on combination with metformin.
3. The method according to claim 1 , wherein said 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1- yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine is administered in an amount of 5 mg once daily to said patient.
4. The method according to claim 1 , wherein said 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine is administered in an amount of 2.5 mg twice daily to said patient.